secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2021-12-01T23:59:59+00:00
Accession:  0001493152-21-030193
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic issues $0.5M in convertible notes at $0.07/share to repay existing debt
--------------------------------------------------------------------------------

- Issued two convertible notes: $0.25M to Talos Victory Fund and $0.25M to Mast Hill Fund.
- Notes carry 12% annual interest, mature in one year, convertible at $0.07 per share.
- Proceeds used to fully repay May 2021 Geneva Note ($203,750) and June 2021 Geneva Note ($103,750).
- Financing round aims for up to $1.0M; first two tranches total $0.5M.
- JH Darbie & Co. entitled to 10% cash finder's fee and 10% warrant coverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315221030193/0001493152-21-030193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315221030193/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-030193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer